Osteoblastic differentiation and potent osteogenicity of three-dimensional hBMSC-BCP particle constructs.
Bone tissue engineering usually consists of associating osteoprogenitor cells and macroporous scaffolds. This study investigated the in vitro osteoblastic differentiation and resulting in vivo bone formation induced by a different approach that uses particles as substrate for human bone marrow stromal cells (hBMSCs), in order to provide cells with a higher degree of freedom and allow them to synthesize a three-dimensional (3D) environment. Biphasic calcium phosphate (BCP) particles (35 mg, ~175 µm in diameter) were therefore associated with 4 × 10(5) hBMSCs. To discriminate the roles of BCP properties and cell-synthesized 3D environments, inert glass beads (GBs) of similar size were used under the same conditions. In both cases, high cell proliferation and extensive extracellular matrix (ECM) production resulted in the rapid formation of thick cell-synthesized 3D constructs. In vitro, spontaneous osteoblastic differentiation was observed in the 3D constructs at the mRNA and protein levels by monitoring the expression of Runx2, BMP2, ColI, BSP and OCN. The hBMSC-BCP particle constructs implanted in the subcutis of nude mice induced abundant ectopic bone formation after 8 weeks (~35%, n = 5/5). In comparison, only fibrous tissue without bone was observed in the implanted hBMSC-GB constructs (n = 0/5). Furthermore, little bone formation (~3%, n = 5/5) was found in hBMSC-macroporous BCP discs (diameter 8 × 3 mm). This study underlines the lack of correspondence between bone formation and in vitro differentiation assays. Furthermore, these results highlight the importance of using BCP as well as a 3D environment for achieving high bone yield of interest for bone engineering.
Inserm U957, Laboratory for Bone Resorption Physiopathology and Primary Bone Tumour Therapy, Faculty of Medicine, University of Nantes, France; EA3855, Laboratory of Haematopoiesis, University François Rabelais, Tours, France.
Thomas
T
Cordonnier
Alain
A
Langonné
Pierre
P
Corre
Audrey
A
Renaud
Luc
L
Sensebé
Philippe
P
Rosset
Pierre
P
Layrolle
Jérôme
J
Sohier
D000368:Aged; D000369:Aged, 80 and over; D000818:Animals; D002454:Cell Differentiation / Q000187:drug effects* / Q000235:genetics; D049109:Cell Proliferation; D005260:Female; D006801:Humans; D006882:Hydroxyapatites / Q000494:pharmacology*; D020007:Implants, Experimental; D008297:Male; D059630:Mesenchymal Stem Cells / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D051379:Mice; D008819:Mice, Nude; D008863:Microspheres; D008875:Middle Aged; D010006:Osteoblasts / Q000166:cytology* / Q000187:drug effects / Q000378:metabolism; D010012:Osteogenesis / Q000187:drug effects* / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D060888:Real-Time Polymerase Chain Reaction; D054457:Tissue Scaffolds / Q000737:chemistry*
D006882:Hydroxyapatites; D012333:RNA, Messenger; C074950:hydroxyapatite-beta tricalcium phosphate